首页> 外文期刊>The Lancet >Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?
【24h】

Tachykinin neurokinin 3 receptor antagonists: a new treatment for cardiovascular disease?

机译:Tachykinin Neurokinin 3受体拮抗剂:一种新的心血管疾病治疗方法?

获取原文
获取原文并翻译 | 示例
           

摘要

Great progress has been made in reducing cardiovascular mortality over the past 50 years. Nevertheless, prevalence is rising in some settings and remains higher in men than in women, even with the same level of established risk factors. To gain new insights, researchers are now considering cardiovascular disease in relation to the well known evolutionary biology model of growth and reproduction trading off against longevity, with trials of calorie restriction underway. However, calorie restriction has not been as successful as expected in primates and it is increasingly realised that effects on the reproductive axis might also be important. In this paper, the modulation of the reproductive axis using existing agents that have such properties-tachykinin neurokinin 3 receptor antagonists-is proposed as a way of reducing cardiovascular disease and combating a leading cause of global morbidity and mortality.
机译:在过去50年来降低心血管死亡率的巨大进展。 然而,普遍存在的某些环境中升高,男性仍然比女性更高,即使具有相同的建立风险因素。 为了获得新的见解,研究人员正在考虑与众所周知的众所周知的生长和繁殖交易抵抗寿命的众所周知的进化生物学模型,进行卡路里限制的试验。 然而,卡路里限制在灵长类动物中预期并未像预期一样成功,越来越明显地意识到对生殖轴的影响也可能是重要的。 本文使用具有如此特性的药剂的生殖轴的调节 - 培养肽神经蛋白3受体拮抗剂 - 被提出为降低心血管疾病,并打击全球发病率和死亡率的主要原因。

著录项

  • 来源
    《The Lancet》 |2017年第10095期|共3页
  • 作者

    Schooling C. Mary;

  • 作者单位

    CUNY Grad Sch Publ Hlth &

    Hlth Policy New York NY USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号